Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Amount
- $400,000
- Closes
- Nov 5, 2028 (in 752 days)
Similar opportunities open now
- Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Nov 2027
- Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2027
- Focused Technology Research and Development (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 2028
- Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 2028
- NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 2028
Classification and identifiers
- Solicitation number
- PAR-25-362
- Assistance listing (CFDA)
- 93.865
Amount
$400,000
Who can apply
Local government agencies, Nonprofits, and State government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.